1 Introduction 14
1.1 Market Definition 14
1.2 Market Scope 15

2 Research Methodology 17
2.1 Primary Research 17
2.2 Research Methodology 18
2.3 Assumptions & Exclusions 19
2.4 Secondary Data Sources 19

3 Market Overview 20
3.1 Report Segmentation & Scope 20
3.2 Value Chain Analysis: Preterm Labor Treatment Market 21
3.3 Key Market Trends 22
3.3.1 Drivers 22
3.3.1.1 Increasing Prevalence of Premature Birth 22
3.3.1.2 Increasing Prevalence of Smoking and Alcohol Consumption 24
3.3.1.3 Increasing Prevalence of Chronic Diseases 24
3.3.1.4 Pregnancy With In Vitro Fertilization 25
3.3.2 Restraint 26
3.3.2.1 Lack of Awareness Regarding Preterm Labor Diagnosis in Developing Regions 26
3.3.3 Opportunities 27
3.3.3.1 Advancements in Diagnosis of Bacterial Vaginosis 27
3.3.3.2 Use of Preterm Labor Drugs to Improve Neonatal Outcomes 28
3.4 Porter's Five Forces Analysis 29
3.4.1 Bargaining Power of Suppliers 29
3.4.2 Bargaining Power of Buyers 30
3.4.3 Threat of Substitution 31
3.4.4 Threat of New Entrants 32
3.4.5 Competitive Rivalry 33

4 Drugs Overview 34
4.1 Introduction 34
4.1.1 Market Size & Forecast 34
4.2 Tocolytic Drugs 35
4.2.1 Market Size & Forecast 35
4.3 Antibiotics Beta - Mimetic 36
4.3.1 Market Size & Forecast 36
4.4 Corticosteroids 37
4.4.1 Market Size & Forecast 37
4.5 Others 38
4.5.1 Market Size & Forecast 38

5 Dosage Form Overview 39
5.1 Introduction 39
5.1.1 Market Size & Forecast 39
5.3 Tablets & Capsules 40
5.3.1 Market Size & Forecast 40
5.4 Injection 41
5.4.1 Market Size & Forecast 41
5.5 Others 42
5.5.1 Market Size & Forecast 42

6 End User Overview 43
6.1 Introduction 43
6.1.1 Market Size & Forecast 43
6.2 Hospitals 44
6.2.1 Market Size & Forecast 45
6.3 Nursing Homes 46
6.3.1 Market Size & Forecast 48
6.4 Others 49
6.4.1 Market Size & Forecast 49

7 Regional Overview 50
7.1 Introduction 50
7.1.1 Market Size & Forecast 50
7.2 North America 51
7.2.1 Market Size & Forecast 53
7.2.1.1 By Drugs 53
7.2.1.2 By Dosage form 54
7.2.1.3 By End Users 54
7.2.2 U.S. 55
7.2.2.1 Market Size and Forecast 55
7.2.2.1.1 By Drugs 56
7.2.2.1.2 By Dosage form 56
7.2.3 Canada 57
7.2.3.1 Market Size and Forecast 57
7.2.3.1.1 By Drugs 57
7.2.3.1.2 By Dosage form 58
7.2.4 Mexico 59
7.2.4.1 Market Size and Forecast 59
7.2.4.1.1 By Drugs 59
7.2.4.1.2 By Dosage form 60
7.3 Europe 61
7.3.1 Market Size & Forecast 62
7.3.1.1 By Drugs 63
7.3.1.2 By Dosage form 63
7.3.1.3 By End Users 64
7.3.2 Germany 65
7.3.2.1 Market Size and Forecast 65
7.3.2.1.1 By Drugs 65
7.3.2.1.2 By Dosage form 66
7.3.3 France 67
7.3.3.1 Market Size and Forecast 67
7.3.3.1.1 By Drugs 67
7.3.3.1.2 By Dosage form 68
7.3.4 UK 69
7.3.4.1 Market Size and Forecast 69
7.3.4.1.1 By Drugs 69
7.3.4.1.2 By Dosage form 70
7.3.5 Italy 71
7.3.5.1 Market Size and Forecast 71
7.3.5.1.1 By Drugs 71
7.3.5.1.2 By Dosage form 72
7.3.6 Spain 73
7.3.6.1 Market Size and Forecast 73
7.3.6.1.1 By Drugs 73
7.3.6.1.2 By Dosage form 74
7.3.7 Rest of Europe 75
7.3.7.1 Market Size and Forecast 75
7.3.7.1.1 By Drugs 75
7.3.7.1.2 By Dosage form 76
7.4 Asia-Pacific 77
7.4.1 Market Size & Forecast 78
7.4.1.1 By Drugs 79
7.4.1.2 By Dosage form 79
7.4.1.3 By End Users 80
7.4.2 Japan 81
7.4.2.1 Market Size and Forecast 81
7.4.2.1.1 By Drugs 81
7.4.2.1.2 By Dosage form 82
7.4.3 China 83
7.4.3.1 Market Size and Forecast 83
7.4.3.1.1 By Drugs 83
7.4.3.1.2 By Dosage form 84
7.4.4 India 85
7.4.4.1 Market Size and Forecast 85
7.4.4.1.1 By Drugs 85
7.4.4.1.2 By Dosage form 86
7.4.5 Australia 87
7.4.5.1 Market Size and Forecast 87
7.4.5.1.1 By Drugs 87
7.4.5.1.2 By Dosage form 88
7.4.6 South Korea 89
7.4.6.1 Market Size and Forecast 89
7.4.6.1.1 By Drugs 89
7.4.6.1.2 By Dosage form 90
7.4.7 Rest of Asia-Pacific 91
7.4.7.1 Market Size and Forecast 91
7.4.7.1.1 By Drugs 91
7.4.7.1.2 By Dosage form 92
7.5 LAMEA 93
7.5.1 Market Size & Forecast 94
7.5.1.1 By Drugs 94
7.5.1.2 By Dosage form 95
7.5.1.3 By End Users 95
7.5.2 Saudi Arabia 96
7.5.2.1 Market Size and Forecast 96
7.5.2.1.1 By Drugs 96
7.5.2.1.2 By Dosage form 97
7.5.3 South Africa 98
7.5.3.1 Market Size and Forecast 98
7.5.3.1.1 By Drugs 98
7.5.3.1.2 By Dosage form 99
7.5.4 Brazil 100
7.5.4.1 Market Size and Forecast 100
7.5.4.1.1 By Drugs 100
7.5.4.1.2 By Dosage form 101
7.5.5 Turkey 102
7.5.5.1 Market Size and Forecast 102
7.5.5.1.1 By Drugs 102
7.5.5.1.2 By Dosage form 103
7.5.6 Rest of LAMEA 104
7.5.6.1 Market Size and Forecast 104
7.5.6.1.1 By Drugs 104
7.5.6.1.2 By Dosage form 105

8 Company Profile 106
8.1 Merck & Co., Inc. 106
8.1.1 Company Overview 106
8.1.2 Financial performance 107
8.1.3 Product Portfolio 109
8.2 Pfizer Inc 110
8.2.1 Company Overview 110
8.2.2 Financial performance 111
8.2.3 Product Portfolio 113
8.3 Novartis AG 114
8.3.1 Company Overview 114
8.3.2 Financial performance 115
8.3.3 Product Portfolio 117
8.4 Sanofi 118
8.4.1 Company Overview 118
8.4.2 Financial performance 119
8.4.3 Product Portfolio 121
8.5 AstraZeneca 122
8.5.1 Company Overview 122
8.5.2 Financial performance 123
8.5.3 Product Portfolio 124
8.6 GlaxoSmithKline plc. 125
8.6.1 Company Overview 125
8.6.2 Financial performance 126
8.6.3 Product Portfolio 127
8.7 Cipla Inc. 128
8.7.1 Company Overview 128
8.7.2 Financial performance 129
8.7.3 Product Portfolio 131



List of Tables

TABLE 1 GLOBAL PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016 - 2026 ($MILLION) 34
TABLE 2 TOCOLYTIC DRUGS MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 35
TABLE 3 ANTIBIOTICS BETA - MIMETIC MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 36
TABLE 4 CORTICOSTEROIDS MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 37
TABLE 5 OTHERS MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 38
TABLE 6 GLOBAL PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016 - 2026 ($MILLION) 39
TABLE 7 TABLETS & CAPSULES, MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 40
TABLE 8 INJECTION, MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 41
TABLE 9 OTHERS, MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 42
TABLE 10 GLOBAL PRETERM LABOR TREATMENT MARKET SHARE, BY END USER, 2016 - 2026 ($MILLION) 43
TABLE 11 HOSPITALS, MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 45
TABLE 12 NURSING HOMES, MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 48
TABLE 13 OTHERS, MARKET SHARE, BY REGION, 2016 - 2026 ($ MILLION) 49
TABLE 14 GLOBAL PRETERM LABOR TREATMENT MARKET SHARE VALUE, 2016 - 2026 ($MILLION) 50
TABLE 15 NORTH AMERICA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY COUNTRY, 2016 - 2026 ($MILLION) 53
TABLE 16 NORTH AMERICA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DRUGS, 2016-2026 ($MILLION) 53
TABLE 17 NORTH AMERICA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DOSAGE FORM, 2016-2026 ($MILLION) 54
TABLE 18 NORTH AMERICA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY END USERS, 2016-2026 ($MILLION) 54
TABLE 19 U.S. PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 56
TABLE 20 U.S. PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 56
TABLE 21 CANADA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 57
TABLE 22 CANADA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 58
TABLE 23 MEXICO PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 59
TABLE 24 MEXICO PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 60
TABLE 25 EUROPE PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY COUNTRY, 2016 - 2026 ($MILLION) 62
TABLE 26 EUROPE PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DRUGS, 2016-2026 ($MILLION) 63
TABLE 27 EUROPE PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DOSAGE FORM, 2016-2026 ($MILLION) 63
TABLE 28 EUROPE PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY END USERS, 2016-2026 ($MILLION) 64
TABLE 29 GERMANY PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 65
TABLE 30 GERMANY PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 66
TABLE 31 FRANCE PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 67
TABLE 32 FRANCE PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 68
TABLE 33 UK PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 69
TABLE 34 UK PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 70
TABLE 35 ITALY PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 71
TABLE 36 ITALY PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 72
TABLE 37 SPAIN PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 73
TABLE 38 SPAIN PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 74
TABLE 39 REST OF EUROPE PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 75
TABLE 40 REST OF EUROPE PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 76
TABLE 42 ASIA-PACIFIC PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY COUNTRY, 2016 - 2026 ($MILLION) 78
TABLE 43 ASIA PACIFIC PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DRUGS, 2016-2026 ($MILLION) 79
TABLE 44 ASIA PACIFIC PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DOSAGE FORM, 2016-2026 ($MILLION) 79
TABLE 45 ASIA PACIFIC PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY END USERS, 2016-2026 ($MILLION) 80
TABLE 46 JAPAN PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 81
TABLE 47 JAPAN PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 82
TABLE 48 CHINA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 83
TABLE 49 CHINA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 84
TABLE 50 INDIA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 85
TABLE 51 INDIA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 86
TABLE 52 AUSTRALIA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 87
TABLE 53 AUSTRALIA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 88
TABLE 54 SOUTH KOREA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 89
TABLE 55 SOUTH KOREA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 90
TABLE 56 REST OF ASIA-PACIFIC PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 91
TABLE 57 REST OF ASIA-PACIFIC PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 92
TABLE 58 LAMEA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY COUNTRY, 2016 - 2026 ($MILLION) 94
TABLE 59 LAMEA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DRUGS, 2016-2026 ($MILLION) 94
TABLE 60 LAMEA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY DOSAGE FORM, 2016-2026 ($MILLION) 95
TABLE 61 LAMEA PRETERM LABOR TREATMENT MARKET SHARE VALUE, BY END USERS, 2016-2026 ($MILLION) 95
TABLE 62 SAUDI ARABIA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 96
TABLE 63 SAUDI ARABIA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 97
TABLE 64 SOUTH AFRICA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 98
TABLE 65 SOUTH AFRICA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 99
TABLE 66 BRAZIL PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 100
TABLE 67 BRAZIL PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 101
TABLE 68 TURKEY PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 102
TABLE 69 TURKEY PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 103
TABLE 70 REST OF LAMEA PRETERM LABOR TREATMENT MARKET SHARE, BY DRUGS, 2016-2026 ($MILLION) 104
TABLE 71 REST OF LAMEA PRETERM LABOR TREATMENT MARKET SHARE, BY DOSAGE FORM, 2016-2026 ($MILLION) 105



List of Figures

FIGURE 1 GLOBAL PREMATURE BIRTH RATE 2015 23
FIGURE 2 BARGAINING POWER OF SUPPLIERS 29
FIGURE 3 BARGAINING POWER OF BUYERS 30
FIGURE 4 THREAT OF SUBSTITUTES 31
FIGURE 5 THREAT OF NEW ENTRANTS 32
FIGURE 6 COMPETITIVE RIVALRY 33
FIGURE 7 PERCENTAGE OF WOMEN ATTENDED ANY HEALTHCARE FACILITY DURING PREGNANCY, 2011-2016 47
FIGURE 8 PERCENTAGE OF WOMEN ATTENDED FOUR OR MORE TIMES ANY HEALTHCARE FACILITY DURING PREGNANCY, 2011-2016 48
FIGURE 9 GLOBAL PRETERM LABOR TREATMENT MARKET, 2016-2026 50
FIGURE 10 NORTH AMERICA PREMATURE BIRTH RATE 2015 (%) 52
FIGURE 11 PRETERM LABOR IN U.S. (%) 52
FIGURE 12 U.S. PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 55
FIGURE 13 CANADA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 57
FIGURE 14 MEXICO PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 59
FIGURE 15 EUROPE PREMATURE BIRTH RATE 2015 (%) 61
FIGURE 16 GERMANY PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 65
FIGURE 17 FRANCE PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 67
FIGURE 18 UK PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 69
FIGURE 19 ITALY PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 71
FIGURE 20 SPAIN PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 73
FIGURE 21 REST OF EUROPE PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 75
FIGURE 22 ASIA PACIFIC PREMATURE BIRTH RATE 2015 77
FIGURE 23 JAPAN PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 81
FIGURE 24 CHINA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 83
FIGURE 25 INDIA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 85
FIGURE 26 AUSTRALIA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 87
FIGURE 27 SOUTH KOREA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 89
FIGURE 28 REST OF ASIA-PACIFIC PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 91
FIGURE 29 LAMEA PREMATURE BIRTH RATE 2015 93
FIGURE 30 SAUDI ARABIA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 96
FIGURE 31 SOUTH AFRICA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 98
FIGURE 32 BRAZIL PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 100
FIGURE 33 TURKEY PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 102
FIGURE 34 REST OF LAMEA PRETERM LABOR TREATMENT MARKET SHARE, 2016-2026 ($MILLION) 104
FIGURE 35 MERCK & CO., INC.: REVENUE ANALYSIS, 2016-2018 ($ MILLION) 108
FIGURE 36 MERCK & CO., INC.: SEGMENT SHARE ANALYSIS 2018 (%) 108
FIGURE 37 MERCK & CO., INC.: REGIONAL SHARE ANALYSIS 2018 (%) 109
FIGURE 38 PFIZER INC.: REVENUE ANALYSIS, 2016-2018 ($ MILLION) 111
FIGURE 39 PFIZER INC.: SEGMENT SHARE ANALYSIS 2018 (%) 112
FIGURE 40 PFIZER INC.: REGIONAL SHARE ANALYSIS 2018 (%) 112
FIGURE 41 NOVARTIS AG: REVENUE ANALYSIS, 2016-2018 ($ MILLION) 115
FIGURE 42 NOVARTIS AG: SEGMENT SHARE ANALYSIS 2018 (%) 116
FIGURE 43 NOVARTIS AG: REGIONAL SHARE ANALYSIS 2018 (%) 116
FIGURE 44 SANOFI: REVENUE ANALYSIS, 2016-2018($ MILLION) 119
FIGURE 45 SANOFI: SEGMENT SHARE ANALYSIS 2018 (%) 120
FIGURE 46 SANOFI: REGIONAL SHARE ANALYSIS 2018 (%) 120
FIGURE 47 ASTRAZENECA: REVENUE ANALYSIS, 2016-2018 ($ MILLION) 123
FIGURE 48 ASTRAZENECA: SEGMENT SHARE ANALYSIS 2018 (%) 124
FIGURE 49 ASTRAZENECA: REGIONAL SHARE ANALYSIS 2018 (%) 124
FIGURE 50 GLAXOSMITHKLINE PLC.: REVENUE ANALYSIS, ($ MILLION) 126
FIGURE 51 GLAXOSMITHKLINE PLC: SEGMENT SHARE ANALYSIS 2018 (%) 127
FIGURE 52 GLAXOSMITHKLINE PLC: REGIONAL SHARE ANALYSIS 2018 (%) 127
FIGURE 53 CIPLA INC: REVENUE ANALYSIS, ($ MILLION) 130
FIGURE 54 CIPLA INC: SEGMENT SHARE ANALYSIS 2018 (%) 130
FIGURE 55 CIPLA INC: REGIONAL SHARE ANALYSIS 2018 (%) 131


Companies Mentioned

• Merck
• Pfizer
• Novartis
• Sanofi
• AstraZeneca
• GSK
• Cipla
• Others